http://ift.tt/eA8V8J
An IRA can be one of the best investments you make, but watch out: moving your money around too often may cost you.
June 14, 2017 at 01:38AM
from
Featured Post
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA)
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA) Please click the li...
Showing posts with label 2017 at 01:39AM. Show all posts
Showing posts with label 2017 at 01:39AM. Show all posts
Wednesday, June 14, 2017
Beware the Limits on IRA Rollovers
The US student medically evacuated from North Korea is in ‘bad shape,’ has been in a coma for a year
June 14, 2017 at 01:34AM
from
Banks Are Becoming Less Safe… Again
http://ift.tt/eA8V8J
by Simon Black via SovereignMan.com, What I’m about to tell you isn’t some wild conspiracy. Or fake news. It’s raw fact, based on publicly available data from the US Federal Reserve. This data shows…
June 14, 2017 at 01:29AM
from IWB
BREAKING: Former Czech president Klaus: The time has come to prepare exit from the EU!
http://ift.tt/eA8V8J
It is time to start preparing the Czech republic at the exit from the European union, it is the only way to “keep and save our state”, said former president Václav Klaus. It bothers…
June 14, 2017 at 01:29AM
from IWB
Obamacare ‘Death Spiral’ One of Most Pressing Issues for Americans Today
Tuesday, June 13, 2017
13 job interview tricks that are hard to master, but will pay off forever
Okay, you’ve wowed your potential employer with your résumé and cover letter. Now, they actually want to talk to you — over the phone, via Skype, or in person.
You can rest assured, you’re definitely qualified for this job. Now, it’s up to you to seal the deal and ace the dreaded job interview.
Some people are naturals at selling themselves to hiring managers. Others aren’t. Either way, you’ve already put in a ton of effort, so you might as well take steps to rock your interview.
Here are 13 tricks that might be hard to master, but will take your interviewing experience to the next level:
SEE ALSO: 11 body language mistakes that will make you seem dishonest in a job interview
DON’T MISS: 23 questions you should never ask at the end of a job interview
Establish the right mindset beforehand
Get yourself hyped for the interview.
This can be pretty difficult for some people, especially if you’ve got a lot on the line. Try taking some deep breaths. A good trick for maintaining a sense of calm is visualizing your success and accepting that rejection’s a possibility, but not an inevitability.
If you’re nervous, as Steve Errey of “The Daily Muse” writes, it’s important not to assume your interviewer is there to be judgmental and mean. The hiring manager is not your opponent — odds are, they’re hoping to feel wowed.
“You were asked to come in because someone at the company wants to get to know you,” says Errey. “The hiring manager wants to hear more about the experiences he read about on paper, and I promise you no one is looking to see how much shaking you can do in those boots of yours.”
Prepare some good questions
Job interviews are scary. By the end of the ordeal, you’re probably thinking that the last thing you want to do is drag on the experience with more questions.
However, asking good questions that demonstrate your knowledge and interest in the job is exactly what you have to do in order to demonstrate your interest and engagement.
Because it’s often impossible for some people to think up informed questions on the spot, write some down beforehand. Rehearse them a bit, if that makes you feel more comfortable.
Break the ice with some good conversation starters
First impressions are important, so you really want to get off on the right foot at your interview.
Still, job interviews are often present a somewhat intimidating conversational environment, so finding the right conversation starter can be pretty tricky. It can be hard to make a perfect first impression when you’re super nervous to begin with.
Rachel Gillett previously reported for Business Insider that the key is making the job interviewer feel like they have your undivided attention; good conversation starters include asking about the person’s weekend or referencing a post you liked from their organization’s blog or social media platforms.
See the rest of the story at Business Insider
June 13, 2017 at 01:33AM
from Áine Cain
6 Money Habits That Could Cripple Your Business Over Time – Entrepreneur
Entrepreneur |
6 Money Habits That Could Cripple Your Business Over Time
Entrepreneur Your company’s finances may be discouraging, but don’t worry: You can still make that monetary U-turn to success. 6 Money Habits That Could Cripple Your Business Over Time. Image credit: Shutterstock. Toby Nwazor. Contributor. Consumer Goods … |
June 13, 2017 at 01:33AM
from
Gainesville woman raises money to pay off school lunch debts – Fauquier Times
Fauquier Times |
Gainesville woman raises money to pay off school lunch debts
Fauquier Times A Gainesville woman has started a campaign to raise money to help pay of school lunch debts in Prince William County. Adelle Settle said she got the idea a few months ago when she heard a story on NPR about public schools in New Mexico that deny … |
June 13, 2017 at 01:33AM
from
Trump likely to get GOP senators’ revised health care draft Tuesday
June 13, 2017 at 01:34AM
from
Algo-trading case: Sebi asks NSE why it didn’t cooperate in probe on unfair access
http://ift.tt/2s3YjoS
June 13, 2017 at 01:30AM
from Jayshree P. Upadhyay
There’s a race to treat a condition that affects 38 million Americans — here’s what you need to know (AMGN, TEVA, LLY, ALDR)
A wave of new preventive migraine medications are on the horizon.
The migraine market is huge. An estimated 38 million Americans have migraines — and Dr. Eric Pearlman, a medical fellow at Lilly, one of the companies developing these treatments, told Business Insider that about 15 million of those migraine sufferers would be eligible for preventive treatment.
Migraines are a chronic neurologic disease that can cause pain, sensitivity to light and noise, dizziness, and nausea. For some, more than four days of the month are consumed by the episodes.
While there aren’t any drugs available today that were originally approved for alleviating migraines, other treatments — including Botox and anti-seizure medications — are used. Pain relievers can also help treat some of the symptoms of migraines.
The new class of drugs aims to reduce the number of days per month people have migraines. By the end of the year, three of these drugs could be in front of the FDA for review. Here’s the skinny on each of them.
- Amgen, erenumab — Amgen filed erenumab with the FDA in May. In data released Thursday, Amgen said its drug was able to reduce the number of migraine days per month by 6.6 days in patients who received the treatment, compared to a 4.2-day reduction in the placebo group. Before the trial, patients had about 18 migraine days.
- Lilly, galcanezumab — Lilly presented phase 3 data on this drug over the weekend. The company found in two studies that pateitns on the drug had between a 3.6 and 4-day reduction in migraine days per month (to be eligible, patients had to have between 4 and 14 migraine days per month). That’s compared to the 2.15 and 1.85 day reduction that was observed in the placebo groups. Lilly said it’s planning to file galcanezumab with the FDA in the second half of 2017.
- Teva, fremanezumab — On June 7, the company came out with data from its late-stage trial. On average, the trial participants had 9.1 migraine days. Those who got the medication had on average 3.7 fewer migraine days per month, compared to 2.2-day reduction in the placebo group. Teva plans to file with the FDA in 2017.
- Alder Biopharmaceuticals, eptinezumab — Alder’s drug is in phase 3 trials. The company plans to submit to the FDA in the second half of 2018.
The new class of drugs target CGRP, short for calcitonin gene-related peptide.
CGRP isn’t exactly a new target. Pearlman said that CGRP has been known to play a significant role in migraines since the 1980s and 1990s, though it’s taken some time to develop the technology that can leverage it.
For now, the drugs are injected typically on a monthly basis, and the most common side effect appears to be reactions at the injection site. Allergan also has a CGRP drug in the works that’s taken as a pill, but it’s a little further back in development. If approved, the drugs are expected to cost $8,500 per year.
SEE ALSO: There’s a race to get 2 revolutionary new cancer treatments on the market — here’s who’s in the lead
Join the conversation about this story »
NOW WATCH: Buying Tesla stock is like buying a call option on Elon Musk
June 13, 2017 at 01:31AM
from Lydia Ramsey
Investors are being told to go scorched earth on the company that makes EpiPen (MYL)
On June 22, Mylan, the maker of EpiPen, will hold a shareholder meeting, and ahead of that meeting shareholders are being advised to vote against almost every single board member at the company — in other words, they’re being told to go scorched earth.
On Monday Institutional Shareholder Services (ISS) released a report recommending shareholders vote against 10 of Mylan’s 11 current board members, including CEO Heather Bresch.
“Because Mylan’s Board has determined that risk oversight is the responsibility of the full board, all incumbent directors should be considered accountable for material failures of risk oversight over a number of years, when warning signs were available to the company but no actions appear to have been taken to mitigate or head off the significant potential risks that have since materialized. Votes against all incumbent directors are considered warranted,” the report said.
Bresch has presided over a disaster. Since Mylan bought EpiPen in 2007, the company raised the price of the life saving anti-allergy medication over 500%. Consumers took notice and took the company to task. Bresch was forced to testify before Congress, and the company’s stock price has plunged nearly 13% over the past year. The company is also accused of overcharging the government for EpiPen by $1.7 billion. Through all that, the price of an EpiPen has not been lowered one cent.
That is, in part, because the price of EpiPen is tied to Mylan’s stock performance, and Mylan’s stock performance is tied to executive compensation. ISS is also recommending that shareholders vote against Mylan’s compensation program.
In agreement with ISS are big shareholders like the New York City and State pension funds and the California Teachers’ Retirement System. They started a “vote no” campaign against the compensation plan and six directors last month.
“The case for holding Mylan’s entrenched Chairman and board accountable could not be stronger. The company’s EpiPen price-hiking debacle spawned a global backlash that hurt both the company’s reputation and share price,” said NYC Comptroller Scott Stringer. “This was ultimately another misstep by a board with a costly history of oversight failures. From Mylan allegedly overcharging the government for life-saving drugs to the board overpaying top executives, it’s clear why share owners are demanding change.”
Another shareholder advisory group, Glass Lewis, is also recommending changes at Mylan. It supports voting “no” on the compensation plan and is advising against three board members, Compensation Committee Chair Wendy Cameron, Audit Committee Chair Neil Dimick , and Compliance Committee Chair Mark Parrish.
Do what you gotta do, guys.
Join the conversation about this story »
NOW WATCH: SCOTT GALLOWAY: WeWork is arguably the most overvalued company in the world
June 13, 2017 at 01:31AM
from Linette Lopez
Subscribe to:
Posts (Atom)